Frazier Taps Former Solera CEO Milton Boyer for Healthcare Deals

Frazier Healthcare Partners just hired someone who doesn't need the job — and that's precisely the point.

The Seattle-based private equity firm announced Monday that Milton Boyer, the former CEO of Solera Holdings and a 30-year veteran of healthcare technology and services, is joining as an Executive in Residence. The move signals Frazier's intention to accelerate dealmaking in healthcare software and services, two categories where operational credibility matters as much as capital.

Boyer isn't joining to retire into advisory work. He'll be sourcing deals, evaluating targets, and — if the thesis holds — stepping into operating roles at portfolio companies where Frazier needs proven leadership fast. It's a model that's gaining traction across the PE landscape: bring in the operator before the deal closes, not after the integration starts falling apart.

The executive-in-residence structure has been around for decades, but it's evolving. Firms aren't just stashing senior talent on retainer for occasional diligence calls. They're embedding operators directly into the investment process — vetting deals, negotiating terms, and pre-wiring post-close transitions. Frazier's betting that Boyer's pattern recognition from Vista Equity Partners, Greenway Health, and Solera will help the firm move faster and mess up less.

Healthcare services and software aren't industries where financial engineering alone delivers alpha. Regulatory complexity, reimbursement risk, clinical workflow integration — these aren't problems you solve with a deck. You need someone who's navigated CMS audits, rebuilt sales teams around value-based care models, and turned around underperforming SaaS products in highly regulated environments.

Boyer checks those boxes. He spent five years as CEO of Solera Holdings, a Vista Equity-backed healthcare technology company, before that business was sold. Prior to Solera, he ran Greenway Health as CEO, a provider of electronic health record and practice management software serving ambulatory care practices. Before that, he held senior roles at Emdeon (now Change Healthcare) and founded MDeverywhere, an early-stage health IT company.

That resume matters because Frazier's investment thesis has shifted. The firm has historically been known for growth equity and venture-stage healthcare deals — backing companies like Zulily (e-commerce), Aledade (value-based care), and Seattle Children's Research Institute spinouts. But the healthcare services and software markets have consolidated. The easy venture-scale exits are harder to find. More deals now involve carve-outs, buy-and-builds, and operational turnarounds — exactly the scenarios where Boyer's background becomes directly monetizable.

Frazier managing partner Ben Magnano said in the announcement that Boyer will help the firm "identify, evaluate, and support investments in healthcare services and software." That's PE-speak for: he'll be in the room when we decide whether to bid, and he might run the thing if we win.

The EIR title used to mean something closer to "senior advisor with an office." Venture firms popularized it as a way to keep successful entrepreneurs in orbit between exits, letting them scout deals and mentor founders without the pressure of building another company. Private equity adopted the model, but with a harder edge: EIRs in PE are often pre-positioned CEOs or functional leaders who'll step into portfolio companies when the timing's right.

What's changing is the timeline. Firms like Frazier are bringing operators in before deals close, not after. The EIR participates in diligence, validates the investment thesis, pressure-tests the management team, and — critically — signals to sellers that the buyer has credible operational leadership ready to deploy. In competitive auctions, that can matter. A seller choosing between two similar bids might tilt toward the firm that's already introduced the incoming CEO.

Boyer's background at Vista Equity Partners is telling. Vista pioneered the industrialized rollup model in software, combining aggressive M&A with a highly prescriptive operational playbook. Vista's EIRs and operating partners don't just advise — they execute. They parachute into portfolio companies, implement margin improvement programs, standardize go-to-market processes, and prepare businesses for the next sale. Boyer spent years in that ecosystem. He knows the playbook.

Frazier isn't the only firm leaning into this model. KKR, Blackstone, and TPG have all expanded their rosters of operating partners and executives-in-residence over the past five years, particularly in sectors like healthcare, software, and industrials where domain expertise translates directly to value creation. The difference now is speed — firms want operators embedded early enough to shape the deal, not just fix it.

Frazier manages approximately $6 billion in assets across growth equity and buyout strategies. The firm's healthcare focus is long-standing, but its mix of deal types has evolved. In recent years, Frazier has moved upmarket — doing larger buyouts, carve-outs from strategics, and buy-and-build platforms in fragmented healthcare services categories.

Boyer's career clusters around three areas that align with where healthcare PE has been most active in the past 24 months: revenue cycle management, EHR/practice management software, and healthcare data infrastructure.

Revenue cycle management — the business of getting healthcare providers paid by insurers — remains one of the stickiest, highest-margin categories in healthcare services. Boyer's time at Emdeon (which became Change Healthcare before its acquisition by UnitedHealth Group) gives him direct exposure to how RCM platforms scale, integrate, and monetize data. That's relevant because Frazier and its peers have been actively consolidating RCM vendors, physician billing services, and claims processing platforms.

EHR and practice management software is a more mature market, but it's fragmenting again. Epic and Cerner dominate hospitals, but ambulatory practices — the segment Boyer served at Greenway — are underserved and price-sensitive. Frazier has historically invested in healthcare IT companies targeting mid-market providers. Boyer's experience selling into and supporting independent practices could help the firm evaluate targets in this segment more precisely.

Healthcare data infrastructure is the wildcard. Boyer's Solera role involved building technology platforms that aggregated and processed healthcare data — work that overlaps with the current investment wave in claims data analytics, prior authorization automation, and interoperability infrastructure. Frazier hasn't been as aggressive in this category as some peers, but Boyer's presence suggests the firm is at least looking harder.

The question is whether Frazier plans to use Boyer for deal sourcing and diligence alone, or whether he's being groomed to run a specific platform the firm is already building. The EIR announcement doesn't specify, but the timing — mid-2026, after a slow M&A market in 2024-2025 — suggests Frazier is positioning for a rebound in healthcare deal activity.

Boyer's Vista pedigree is worth unpacking. Vista's model — buy software companies, apply a standardized operational playbook, roll up adjacent assets, exit at higher multiples — has influenced nearly every software-focused PE firm over the past decade. Vista's operating partners aren't decorative. They're implementers. They show up with checklists, benchmarks, and timelines. They don't wait for management to propose a plan; they install one.

That approach has been slower to take hold in healthcare services, where regulatory risk and clinical complexity make standardization harder. But it's coming. Frazier hiring someone who's seen the Vista playbook up close suggests the firm believes parts of that model — especially around sales efficiency, margin optimization, and M&A integration — can translate to healthcare software and tech-enabled services.

Not every senior executive works as an EIR. The role requires a specific combination of skills that doesn't overlap perfectly with being a great CEO.

First, pattern recognition. An EIR sees dozens of deals a year. The job is to quickly assess whether a target's financials, competitive position, and management team are real or theater. That requires deep operational experience across multiple companies — not just one successful run. Boyer's worked at a founder-led startup, a public company, and two private equity-backed businesses. He's seen the lifecycle.

Second, ego management. EIRs don't get to be the hero. They diligence deals that don't close. They recommend passes on investments the team loves. They step into portfolio companies where the founder-CEO just got fired, and the employees resent the new regime. That's not a job for someone who needs to be the visionary. It's a job for someone who's okay being the mechanic.

Third, transactional fluency. EIRs spend time with investment bankers, lawyers, and financial sponsors. They need to speak that language without getting lost in it. Boyer's been through multiple M&A exits — as a seller, as an operator during ownership transitions, and as a Vista-backed CEO managing bolt-on acquisitions. He's sat on both sides of the table.

Frazier isn't unique in trying to stockpile operating talent. The entire healthcare PE ecosystem is doing it. Firms are competing not just for deals, but for the people who can run them.

The scarcity isn't capital — dry powder in healthcare-focused PE funds hit record levels in 2025. The scarcity is credible operators who understand both healthcare delivery and modern software/data businesses. There aren't that many people who've run a healthcare SaaS company through a PE ownership cycle, dealt with CMS regulatory changes, and rebuilt a go-to-market team around value-based care. Boyer's one of them.

The firms winning deals in healthcare today are the ones that can show sellers a credible Day 100 plan — who's running it, how they'll integrate it, what the cost synergies look like, and when the follow-on acquisitions start. Boyer gives Frazier a more credible answer to all of those questions.

There's also a defensive element. If Frazier doesn't hire Boyer, someone else will. The market for senior healthcare tech operators is tight enough that firms are poaching each other's executives-in-residence before they formally join. One firm recently lost an EIR candidate to a competitor during the final negotiation because the rival offered a co-investment stake in the next platform deal. Talent retention in PE is starting to look like talent retention in venture.

The most interesting scenario isn't Boyer staying in the EIR seat indefinitely. It's Boyer moving from EIR to CEO of a new Frazier platform within 12-18 months.

Here's the pattern to watch: Frazier announces a new healthcare services or software investment in the next two quarters. The target is either a carve-out from a larger company or a founder-led business where the founder is ready to step back. The press release names Boyer as incoming CEO. Frazier uses the next 24 months to bolt on three to five adjacent businesses. The combined entity exits to a strategic or larger PE firm at a premium multiple.

That's the playbook. And if it works, expect more firms to copy it — not just in healthcare, but across any sector where operational complexity creates a moat that financial buyers can't cross without the right people.

The alternative is that Boyer stays in the EIR role longer-term, cycling through diligence processes and board seats without stepping into a full-time operating role. That's fine, but less interesting. The real value of an EIR isn't what they see — it's what they do with what they've seen.

The timing of Boyer's hire is worth interrogating. Why is Frazier adding an EIR focused on healthcare services and software in mid-2026?

One explanation: the firm sees a wave of deals coming. M&A activity in healthcare slowed significantly in 2024-2025 as interest rates stayed elevated and valuation expectations between buyers and sellers stayed far apart. But that's thawing. Private equity firms are sitting on record levels of uninvested capital. Strategic buyers in healthcare are under pressure to grow inorganically because organic growth has stalled. Sellers who held out for 2023-era valuations are starting to capitulate.

Another explanation: Frazier has a specific deal in the pipeline and needed the operational credibility to close it. Bringing Boyer on as EIR signals to a seller that Frazier isn't just another financial buyer. They've got the CEO ready to go. That can matter in competitive situations, especially when the seller cares about legacy and employee retention.

A third explanation: Frazier is preparing to raise its next fund and wants to demonstrate to LPs that it has the operational infrastructure to execute on larger, more complex buyouts. Adding a senior EIR with Boyer's pedigree sends that signal. It says: we're not just a growth equity shop anymore. We can do the hard stuff.

All three could be true simultaneously. But the timing — hiring someone of Boyer's caliber in June 2026, after the deal market has started to recover but before the next valuation reset — suggests Frazier is positioning for acceleration, not waiting for clarity.